Management of drug-related problems including drug-drug interactions caused by nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2.

Yalcin, Nadir; Demirkan, Kutay

Yalcin, Nadir; Demirkan, Kutay.

Afiliação

Yalcin N; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey nadir.yalcin@hotmail.com.
Demirkan K; Department of Clinical Pharmacy, Erasmus MC, Rotterdam, The Netherlands.

Arch Dis Child ; 108(10): e16, 2023 10.

Article em En | MEDLINE | ID: mdl-36180113

Assuntos

COVID-19; Ritonavir; Humanos; Criança; Ritonavir/efeitos adversos; SARS-CoV-2; Tratamento Farmacológico da COVID-19

Palavras-chave

global health; infectious disease medicine; pharmacology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Ritonavir / COVID-19 Limite: Child / Humans Idioma: En Revista: Arch Dis Child Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google